<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Entrada Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/entrada-therapeutics-inc</link>
<description>Latest news and press releases for Entrada Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Feb 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/entrada-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cb7c78dffbe2df11d2cd.webp</url>
<title>Entrada Therapeutics Inc</title>
<link>https://6ix.com/company/entrada-therapeutics-inc</link>
</image>
<item>
<title>Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data</description>
</item>
<item>
<title>Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/independent-data-monitoring-committee-recommends-initiation-of-cohort-2-at-the-increased-dose-of-12-mgkg-in-entrada-therapeutics-elevate-44-201-study</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/independent-data-monitoring-committee-recommends-initiation-of-cohort-2-at-the-increased-dose-of-12-mgkg-in-entrada-therapeutics-elevate-44-201-study</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients who completed dosing in Cohort 1 of the double-blinde</description>
</item>
<item>
<title>Entrada Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-present-upcoming-investor-120000962</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-present-upcoming-investor-120000962</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March</description>
</item>
<item>
<title>Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-highlights-progress-across-120000000</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-highlights-progress-across-120000000</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 20</description>
</item>
<item>
<title>Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-present-44th-annual-120000771</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-present-44th-annual-120000771</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the e</description>
</item>
<item>
<title>Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-inducement-grants-213000813</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-inducement-grants-213000813</guid>
<pubDate>Thu, 04 Dec 2025 21:30:00 GMT</pubDate>
<description>BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of December 1, 2025. The options have an exercise price of $9.91 per share, which is equal to the closing price of the Com</description>
</item>
<item>
<title>Entrada Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-third-quarter-120000214</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-third-quarter-120000214</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 with $327 million in cash, cash equivalents and marketable securities as of September 30, 2025 -- BOSTON,</description>
</item>
<item>
<title>Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-recipients-third-110000823</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-recipients-third-110000823</guid>
<pubDate>Fri, 05 Sep 2025 11:00:00 GMT</pubDate>
<description>-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness Day on September 7, grants are designed to fund projects supporting the Duchene community on a global scale -- BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its third annual DRE</description>
</item>
<item>
<title>Entrada Therapeutics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-second-quarter-110000397</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-second-quarter-110000397</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expecte</description>
</item>
<item>
<title>Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-appoints-maha-radhakrishnan-110000030</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-appoints-maha-radhakrishnan-110000030</guid>
<pubDate>Tue, 03 Jun 2025 11:00:00 GMT</pubDate>
<description>Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be inv</description>
</item>
<item>
<title>Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-european-110000375</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-european-110000375</guid>
<pubDate>Wed, 28 May 2025 11:00:00 GMT</pubDate>
<description>– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multip</description>
</item>
<item>
<title>Entrada Therapeutics Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-first-quarter-110000991</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-first-quarter-110000991</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics</description>
</item>
<item>
<title>Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-united-110000324</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-united-110000324</guid>
<pubDate>Mon, 24 Mar 2025 11:00:00 GMT</pubDate>
<description>– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulator</description>
</item>
<item>
<title>Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-fourth-quarter-120000132</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-fourth-quarter-120000132</guid>
<pubDate>Thu, 27 Feb 2025 12:00:00 GMT</pubDate>
<description>– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reporte</description>
</item>
<item>
<title>Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-fda-removal-120000779</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-announces-fda-removal-120000779</guid>
<pubDate>Mon, 24 Feb 2025 12:00:00 GMT</pubDate>
<description>– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-44-201-a-phase-12-multiple-ascending-dose-clinical-study-of-entr-601-44-in-patients-living-with-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-receives-authorization-in-the-united-kingdom-to-initiate-elevate-44-201-a-phase-12-multiple-ascending-dose-clinical-study-of-entr-601-44-in-patients-living-with-duchenne-muscular-dystrophy</guid>
<pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
<description>– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU,</description>
</item>
<item>
<title>Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Wed, 18 Dec 2024 05:00:00 GMT</pubDate>
<description>BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the</description>
</item>
<item>
<title>Entrada Therapeutics Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-reports-third-quarter-2024-financial-results</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle</description>
</item>
<item>
<title>Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-presents-new-data-supporting-its-expanding-duchenne-franchise-at-the-29th-annual-congress-of-the-world-muscle-society</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-presents-new-data-supporting-its-expanding-duchenne-franchise-at-the-29th-annual-congress-of-the-world-muscle-society</guid>
<pubDate>Wed, 09 Oct 2024 04:00:00 GMT</pubDate>
<description>– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned</description>
</item>
<item>
<title>Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development</title>
<link>https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-promotes-natarajan-sethuraman-phd-to-president-of-research-and-development</link>
<guid isPermaLink="true">https://6ix.com/company/entrada-therapeutics-inc/news/entrada-therapeutics-promotes-natarajan-sethuraman-phd-to-president-of-research-and-development</guid>
<pubDate>Tue, 24 Sep 2024 04:00:00 GMT</pubDate>
<description>BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the</description>
</item>
</channel>
</rss>